{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:58:13Z","timestamp":1757577493687},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,12]]},"DOI":"10.7759\/cureus.29094","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T03:53:37Z","timestamp":1663041217000},"source":"Crossref","is-referenced-by-count":3,"title":["The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study"],"prefix":"10.7759","author":[{"given":"Bharat","family":"Vaswani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palanki S","family":"Dattatreya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar B","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit Y","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.776541","article-title":"Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients","volume":"14","author":"Janelsins MC","year":"2013","unstructured":"Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013, 14:757-66. 10.1517\/14656566.2013.776541","journal-title":"Expert Opin Pharmacother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura K","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, et al.. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015, 20:855-65. 10.1007\/s10147-015-0786-7","journal-title":"Int J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00329","article-title":"Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review","volume":"11","author":"Mosa AS","year":"2020","unstructured":"Mosa AS, Hossain AM, Lavoie BJ, Yoo I. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol. 2020, 11:329. 10.3389\/fphar.2020.00329","journal-title":"Front Pharmacol"},{"key":"ref4","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in Antiemetic 2021. (2021). Accessed:  December 21, 2021: https:\/\/www.nccn.org\/professionals\/physician_gls."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh PJ","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al.. Antiemetics: ASCO guideline update. J Clin Oncol. 2020, 38:2782-97. 10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila F","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, et al.. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016, 27:v119-33. 10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00400","article-title":"Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective","volume":"10","author":"Vaid AK","year":"2020","unstructured":"Vaid AK, Gupta S, Doval DC, et al.. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol. 2020, 10:400. 10.3389\/fonc.2020.00400","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08342-1","article-title":"The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting","volume":"21","author":"Vaswani B","year":"2021","unstructured":"Vaswani B, Dattatreya PS, Bhagat S, Patil S, Barkate H. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting. BMC Cancer. 2021, 21:601. 10.1186\/s12885-021-08342-1","journal-title":"BMC Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i8.606","article-title":"Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: a real-life study from India","volume":"11","author":"Vaswani B","year":"2020","unstructured":"Vaswani B, Bhagat S, Patil S, Barkate H. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: a real-life study from India. World J Clin Oncol. 2020, 11:606-13. 10.5306\/wjco.v11.i8.606","journal-title":"World J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh PJ","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, et al.. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014, 25:1340-6. 10.1093\/annonc\/mdu110","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro M","year":"2014","unstructured":"Aapro M, Rugo H, Rossi G, et al.. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014, 25:1328-33. 10.1093\/annonc\/mdu101","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"Gralla RJ","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, et al.. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014, 25:1333-9. 10.1093\/annonc\/mdu096","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine I","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013, 104:711-7. 10.1111\/cas.12146","journal-title":"Cancer Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-017-0761-4","article-title":"Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients","volume":"24","author":"Uomori T","year":"2017","unstructured":"Uomori T, Horimoto Y, Mogushi K, Matsuoka J, Saito M. Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients. Breast Cancer. 2017, 24:702-7. 10.1007\/s12282-017-0761-4","journal-title":"Breast Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2015.12.317","article-title":"Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: results from the Pan European Emesis Registry study","volume":"51","author":"Molassiotis A","year":"2016","unstructured":"Molassiotis A, Lee PH, Burke TA, Dicato M, Gascon P, Roila F, Aapro M. Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: results from the Pan European Emesis Registry study. J Pain Symptom Manage. 2016, 51:987-93. 10.1016\/j.jpainsymman.2015.12.317","journal-title":"J Pain Symptom Manage"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/651879","article-title":"A review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomiting","volume":"2015","author":"Hesketh PJ","year":"2015","unstructured":"Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H. A review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomiting. Biomed Res Int. 2015, 2015:651879. 10.1155\/2015\/651879","journal-title":"Biomed Res Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.080","article-title":"Chemotherapy-induced nausea and vomiting (CINV) - incidence by age and sex among patients receiving oxaliplatin","volume":"21","author":"Binder G","year":"2018","unstructured":"Binder G, Saunders WB. Chemotherapy-induced nausea and vomiting (CINV) - incidence by age and sex among patients receiving oxaliplatin. Value Health. 2018, 21:S14. 10.1016\/j.jval.2018.04.080","journal-title":"Value Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5250","article-title":"Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial","volume":"4","author":"Wang DS","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, et al.. Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open. 2021, 4:e215250. 10.1001\/jamanetworkopen.2021.5250","journal-title":"JAMA Netw Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0737-9","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh PJ","year":"2010","unstructured":"Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010, 18:1171-7. 10.1007\/s00520-009-0737-9","journal-title":"Support Care Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S254398","article-title":"Efficacy of olanzapine-triple antiemetic regimen in patients with gastrointestinal tumor and high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: a retrospective study","volume":"12","author":"Wu X","year":"2020","unstructured":"Wu X, Wu J, Tong G, et al.. Efficacy of olanzapine-triple antiemetic regimen in patients with gastrointestinal tumor and high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: a retrospective study. Cancer Manag Res. 2020, 12:6575-83. 10.2147\/CMAR.S254398","journal-title":"Cancer Manag Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris G","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, et al.. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017, 28:1260-7. 10.1093\/annonc\/mdx100","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/109353-the-effectiveness-of-an-oral-fixed-dose-combination-of-netupitant-and-palonosetron-nepa-in-patients-with-multiple-risk-factors-for-chemotherapy-induced-nausea-and-vomiting-a-multicenter-observational-indian-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:18Z","timestamp":1707508038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/109353-the-effectiveness-of-an-oral-fixed-dose-combination-of-netupitant-and-palonosetron-nepa-in-patients-with-multiple-risk-factors-for-chemotherapy-induced-nausea-and-vomiting-a-multicenter-observational-indian-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.29094","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,12]]}}}